# FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

> **NCT00325442** · PHASE3 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 354 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Oral treprostinil (UT-15C) sustained release tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00325442
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-09
- **Final completion:** 2010-12
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00325442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00325442, "FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00325442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*